Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...

We recently published a list of These 10 Stocks Were Wednesday’s Worst Performers. In this article, we are going to take a ...

Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product ...

Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

The mRNA pioneer sees considerable uncertainty in the vaccine market. However, Moderna still expects 10 product approvals over the next three years that could fuel growth. The conventional ...

Although the stock market was having a generally strong week, that isn't the case for vaccine technology company Moderna (NASDAQ: MRNA). The main reason for this week's decline is that Moderna lowered ...

Detailed price information for JP Morgan Chase & Company (JPM-N) from The Globe and Mail including charting and trades.

Goldman Sachs downgraded Moderna (MRNA) to Neutral from Buy with a price target of $51, down from $99. The recent product revenue guidance ...

Since the market is focusing on the COVID vaccine performance and overlooking the revenue opportunity that Moderna's product candidates have, I believe long-term investors are likely to get rewarded.

Moderna wins EU tender to supply COVID-19 vaccines for up to four years, offering diverse formats like prefilled syringes to ...

Leerink Partners analyst Mani Foroohar has maintained their bearish stance on MRNA stock, giving a Sell rating yesterday.Invest with ...